BCIQ Profiles

Company Profile ReportTarget Profile Report

J&J's Balversa gets accelerated approval for bladder cancer

FDA granted Janssen's Balversa erdafitinib accelerated approval to treat bladder cancer, making it the first FGFR kinase inhibitor to gain U.S. approval.

Balversa is indicated

Read the full 242 word article

How to gain access

Continue reading with a
two-week free trial.